StockData
CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$1.99−0.05 (-2.70%)

Close on Nov 16, 2026Market cap $432.53MP/E –Yield –

CytomX Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

CytomX Therapeutics's ebitda for the twelve months ending Jun 30, 2019 was -$94.46M. For fiscal 2018 it was -$75.99M. The highest annual figure on record is -$14.30M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2018Dec 31, 2018-$75.99M–
FY2017Dec 31, 2017-$44.61M–
FY2016Dec 31, 2016-$57.85M–
FY2015Dec 31, 2015-$32.00M–
FY2014Dec 31, 2014-$28.98M–
FY2013Dec 31, 2013-$14.30M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2019Jun 30, 2019-$30.60M–
Q1 FY2019Mar 31, 2019-$15.95M–
Q4 FY2018Dec 31, 2018-$25.20M–
Q3 FY2018Sep 30, 2018-$22.70M–
Q2 FY2018Jun 30, 2018-$12.83M–
Q1 FY2018Mar 31, 2018-$15.25M–
Q4 FY2017Dec 31, 2017-$843.00K–
Q3 FY2017Sep 30, 2017-$10.55M–
Q2 FY2017Jun 30, 2017-$25.00M–
Q1 FY2017Mar 31, 2017-$8.22M–
Q4 FY2016Dec 31, 2016-$13.74M–
Q3 FY2016Sep 30, 2016-$14.47M–

More CytomX Therapeutics figures

See a number that looks wrong?